Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07215260) titled 'A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body' on Oct. 9.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Boehringer Ingelheim
Condition:
Healthy
Intervention:
Drug: BI 3000202
Drug: Rosuvastatin
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: November 4, 2025
Target Sample Size: 14
Countries of Recruitment:
Germany
To know more, visit https://clinicaltrials.gov/s...